067 Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials

• Jeffrey A Cohen,
• Giancarlo Comi,
• Ludwig Kappos,
• Sarah Harris,
• Lawrence Steinman,
• Bruce AC Cree,
• James K Sheffield,
• Harry Southworth

Affiliations

Jeffrey A Cohen

1 Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA

Giancarlo Comi

1 Institute of Experimental Neurology (InSpe), Division of Neuroscience, IRCCS Ospedale San Raffaele, Milano, Italy

Ludwig Kappos

2 Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland

Sarah Harris

2Department of Psychology, University of Bath, Bath, UK

Lawrence Steinman

4Stanford University School of Medicine, USA

Bruce AC Cree

3Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA

James K Sheffield

1Bristol Myers Squibb, Princeton, New Jersey, USA

Harry Southworth

5Data Clarity Consulting Ltd, Stockport, UK